dow logo

Dow-Chemical selling chunk of chlorine business to Olin Corp in a $5 billion deal

Written by Joseph Nordqvist

Published: 17:25, March 27, 2015

Dow-Chemical Co announced that it is going to spin off a portion of its chlorine business to Olin Corp, in a cash and stock deal worth $5 billion.

Dow shareholders will own 50.5 percent of Olin and the company will designate three directors to Olin’s board.

The Michigan-based company is moving away from chlorine as part of an effort to focus more on higher-margin products.

dow chemical company logo

Olin will become the world’s largest producer of chloe-alkali after the sale is completed. Chlor-alkali is used to create caustic soda and chlorine, which are used in a range of industries such as automotive, healthcare, and textiles.

Activist investor Dan Loeb has been pressuring Dow-Chemical to sell its low-margin bulk chemicals businesses. An activist investor is a person or group that becomes a significant minority shareholder in a company and tries to influence its management.

The company first announced that it would be selling a portion of its chlorine business in 2013, stating that it would be shedding off at least $5 billion worth of low-margin businesses.

Dow Chemical Chief Executive Andrew Liveris said in a conference call with investors earlier that the deal shows how “Dow continues to behave as our own, best activist.”

He also said that there may be more deals over the next year as the company simplifies its joint ventures.

“JV conversations are ongoing right now and we are seeking the right strategic answers,”



Dow will be selling its chlorine in a “tax-efficient” way. It will receive $2 billion in cash and cash equivalents in addition to around $2.2 billion in Olin shares in a Reverse Morris Trust deal.

Under the deal Oline will assume $800 million of pension and liabilities and it will give Dow shareholders control of the firm.

Olin Chief Executive Joseph Rupp said that the combined business will be in a better position as the chlor-alkali market improves in North America.

The deal is expected to be completed by the year-end.

Dow’s financial advisers were Barclays Plc and Goldman Sachs Group Inc. and its legal counsel was Shearman & Sterling LLP. Olin’s financial adviser was JPMorgan Chase & Co. and its legal counsel was Cravath Swaine & Moore LLP.


Joseph Nordqvist Avatar

Other News

AI system helps robots perform learned tasks up to 3.2 times faster

Aug 8, 2026

Meaningful work may come from accepting career uncertainty

Aug 8, 2026

Nvidia reportedly plans up to $3 billion investment in Lancium

Aug 8, 2026

Why businesses are being urged to prepare for tighter microplastics rules

Aug 7, 2026

Retiring a working gasoline car for an EV can cut lifetime emissions, study finds

Aug 7, 2026

U.S. businesses produced more per hour, but labor’s share of output hit a record low

Aug 6, 2026

Researchers test continuous method for making leather-like fabric from fungal mycelium

Aug 6, 2026

U.S. renters expect to move less as homeownership feels further out of reach

Aug 6, 2026

CEO confidence turns positive as pessimism recedes, but investment remains cautious

Aug 6, 2026

Digital tools could reshape women’s entrepreneurship, suggest researchers

Aug 5, 2026

Success can make people learn less from their own mistakes, study suggests

Aug 5, 2026

Shopify data suggests AI search is giving niche products a new route to customers

Aug 5, 2026

Customer data is moving deeper into pricing decisions

Aug 5, 2026

Texas pauses data-center grid connection approvals as power queue reaches 474 gigawatts

Aug 4, 2026

Japan tests whether carbon pulled from seawater can fuel planes

Aug 4, 2026

Expressive robots engage people more, but their mistakes carry a higher social cost

Aug 4, 2026

Employees reported a better work experience after hybrid work was introduced

Aug 4, 2026

Tomato gene helps plants recover after drought in controlled tests

Aug 4, 2026

New process could reduce the need to purify factory carbon dioxide before reuse

Aug 4, 2026

More novel drugs gained revenue faster in the U.S. after 2013

Aug 3, 2026